TW436295B - Concentrated aqueous solutions of argatroban - Google Patents
Concentrated aqueous solutions of argatroban Download PDFInfo
- Publication number
- TW436295B TW436295B TW084100521A TW84100521A TW436295B TW 436295 B TW436295 B TW 436295B TW 084100521 A TW084100521 A TW 084100521A TW 84100521 A TW84100521 A TW 84100521A TW 436295 B TW436295 B TW 436295B
- Authority
- TW
- Taiwan
- Prior art keywords
- solution
- cell
- group
- patent application
- item
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Luminescent Compositions (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Description
經濟部中央標準局貝工消费合作社印掣 Μ 乙油 了問 ,進 , 、 麻 。生重.e)增 劑 醇蓖 度發藤qu能 加丙或 解都的nl其 添 、酯 溶乎上ch, 些醇酐 的幾應er方 某乙酵 班液反 t 配 用議糖 托溶般le葯 使建梨 加的一el製 以 已山。阿成的1C的 可 究如用加所類 m 班 們研 t 使增劑之ed托 我。術劑 1 能加應IX加。 , 度學化少確添反 U 阿度 積濃的活的劑種性 術的解 體的中面} 加各敏 技穎溶 的液行表物添上過 胞新的 食溶進、生些 W 或 微m水 服班有醇衍某加/型一於 少托現二之的添及 合出解 減加,乙化中,力 混展溶 了阿如聚氧其是药 用發班 為進例、乙這但耐 利已托 增 醇聚 部。 前加 便 二的 局題 目阿 ^ 436295 ^ 五、發明説明(ί ) 發明簡逑: 一種濃締之阿加托班水溶液*含有阿加托班、一種激 胞彤成劑、及一種類脂化合物。 發明詳述: 本發明傣關於一種阿加托班U r g a t r 〇 b a η)的新穎製药 配方。 眄加托班是一種人工合成的凝血胸抑制劑,羼於一種 微溶於水的化合物(約1 Bg/Bl)。 如果阿加托班是圼純水溶液的形式,則茌治療某些症 候時 > 為達其所需的劑量,患者往往必須一天内服食數百 毫升。 本紙張尺度適用中國國家揉準(CNS ) Α4規格(210X297公釐) J--------1 裝------訂-----I:旅 ** (請先閲讀背面之注項再填寫本頁) 經濟部中央標準局貝工消費合作社印製 卜43以95 Λ7 B7 五、發明説明(>) 此製药配方係把微胞形成劑(micelle-forming agent )及類脂化合物(1 i P 〇 i d ),如磷脂等,與阿加托班结合在 一起。 本製药配方亦可含有那些製餚液態葯劑經常添加的添 加劑’例如容模劑(osmolarity agents)、嫒衝劑(buffer agents)、抗氧 ib 劑(antioxidants)、及防腐劑(preserv a tives),或者亦可含有那些製備乾燥葯劑經常添加的添加 劑(乾燥形式是Μ泠涑乾燥、噴蓀乾燥、霧化乾燥等達成 ),乾燥葯劑在重组之後,即可轉化為液態形式。 所使用的微胞形成劑可由通式(I)的膽酸衍生物製成
其中’ Rl、R2及R3各代表氫原子、羥基、或氧代環外 基圑(keto exocyclic group) ,R4則代表羧基、或是一 種其醯胺鍵(amide)鐽接至氨基酸之氨基的羧基; 其甾族(steroid)結構中,可含有一個或兩個雙鍵, 聱如在7 - 8、1卜1 2、或9 - 11的位置。 本紙張尺度逋用中國國家橾準(CNS ) A4規格(210X297公釐) 「™-裝 I I ί 訂! "線 - -(請先閣讀背面之注意事項再填寫本頁) 5 A7 B7 經濟部中央榡準局負工消費合作社印製 五、發明説明(4 ) 更明確而言*本發明所使用之式(I)化合物中的R1、 R 2、R 3及R 4代表下列基團: R1、R2、R3 = 0 H, R4 = COOH Rl、 R2、 R3 = OH, R4 = C0NH-CH2-C00H R1 ' R2 ' R3 = OH, R4 = C0NΗ-CΗ 2-CΗ 2-S03 Η Rl' R3 = OH , R2 = H, R4 = COOH Rl' R3 = OH, R2 = H, R4 = C0NH-CH2-C00H R1 > R3 = OH, R2 = H, R4 = C0NH-CH2 - CH2 - S03H R1、= OH, R3 = H, R4 二 COOH R1 ' R2 = OH , R3 = H, R4 = C0NH-CH2-C00H R 1、R 2 = 0 H , R 3 = H,R 4 = C 0 iJ H - C H 2 - C H 2 - S 0 3 H 式(I)化合物的使用形式可為鹽、尤其是鹼金屬鹽* 特別是納鹽。 作為類脂化合物,下列化合物特別適用: ~ 碟脂醒膽驗(phosphatidylcholines) ~ 鱗脂魅乙酵胺(phosphatidylethanolamine) ~ 磷脂醢Μ胺(phosphatidylinositol) 一.磷脂醢絲氨酸(phosphatidylserines) — 二碟脂藤丙三醇(diphosphatidylglycerol) ~ 甘油醚鱗脂(glyce.rine ether-phosphatides) ~ 血漿脂(plasmalogens) ~ (神經)鞘磷脂(sphingomyelin) ~ 硫脂及甘油酸腊(sulphatides and monoglycerines) (請先閲讀背面意事項再填寫本頁) —ί— 背面^d τ .裝· 、ΤΓ 本 表紙張尺度通用中國國家標隼(CMS ) A4現格(210X297公釐) 經濟部中夬榡準局員工消费合作杜印製 436295 A7 B7 i、發明説明(·〇 其中較好是磷脂(phosphatides),尤其是磷脂醯膽酸 (Phosphatidylcholines)。 微胞形成劑得為兩種或Μ上之膽酸衍生物的混合物。 兩棰或以上之類脂化合物的混合物亦可使用於本發明。 類脂化合物對微胞彤成成份(純化合物或混合物)的 克分子比是介於0 . 1 / 1至2 / 1之間,較好是介於0 , 5 /1至1 . 5 /1之間。 依據本發明所製成之药劑配方,最终微胞形成劑在配 方中之濃度,通常是介於0 . 0 1Μ至0 · 5 Μ之間,.其濃度為所 霈阿加托班之湄度的可變函數。 依據本發明的阿加托班溶液得ΚΜ下方法製備: 1 ·採取剌烈攪拌,.把全部成份溶解於水。 2 ·把混合之微胞成份溶解於大致為稀的有櫬溶劑,之後 把溶劑蒸發掉*接著把殘留物萃取於水中(水中可添 加其它必須的賦彤劑Κ調其ΡΗ值、容模值及/或其它 必須的賦形劑以增進溶液的安定度,最後*配合攪拌 動作把阿加托班加入。 3 ·把阿加托班與微胞成份溶解於有機溶劑,之後把溶劑 蒸發掉,接著把殘留物萃取於水中(水中可添加上述 第2點所述之賦形劑)。 如此所製得之溶液,其阿加托班濃度大於1 ni g / m 1,更 明而言,係介於1 mg/ml至2liBg/ml之間。 本紙張又度通用中國國家標準{ CNS ) A4規格(210X297公釐> --------^、續裝------.訂-----(,:-^ (請先閲讀背面之注意#'項再填寫本頁) k4362 9 f
經濟部中央揉準局負工消费合作社印策 五、發明説明(Μ 對於以上述任何一種方式製成的溶液而言,可从加入 一種或多種基質,例如單糖、寡糖、多元醇、氨基酸、聚 合物,如聚乙基比咯烷酮、明膠、葡聚糖、白朊等,添加 濃度介於Q · 1至2 Q %之間。 製成物接著以噴羅乾燥法或低壓凍乾法加κ乾燥。 所製成之固體物質(:須貯存於密封容器内及受控制的 大氣壓力下)在需要用到時,可添加至適當溶劑中,例如 水,Μ備注射之用。 如此一來,可製得清激的溶液.,其漶度介於lBg/*l至 21 mg/ml之間。 以下實例可進一步閫明本發明: 審 例 1 把1 · 2克的純淨卵磷脂、〇· 7克的甘膽酸鈉(sodium glyco-cholate)及0.12 5克的阿加托班溶解於75毫克的95¾乙醇, 並Μ磁力攬拌。之後,在滅壓下把乙醇蒸發掉,接著在室 溫下,配合授拌在25毫克的Q.Q6M的磷酸鑀衝液(ρΗ=6) 中萃收殘留物。如此可製得清激溶液,其濃度為5ing/ml。 此溶液在+ 4¾的貯存溫度,可維持安定數週之久。 審剜 2 把0 · 7 5 0克的纯淨卵磷脂、〇 . 4 9 ϋ克的甘膽酸納(s 〇 d i um glycocholate)溶解於10毫升的95%乙醇。在減壓下把乙酵 蒸發掉之後•把殘留物溶解於15奪升的0.06M的磷酸縵衝 液(pH= 6 ),配合澈烈攪拌,加入0.1Q0克的阿加托班。 本紙乐尺度適用中國國家揉準(CNS > A4規格(2丨OX297公釐) J^l^l Ji (请先聞讀背面之注意事項存填薄本買·- ir γ 436295 at Β7 五、發明説明(6 ) 在通入氮氣氣泡下,維持攪拌達數小畤,之後,以添加磷 酸嫌衝液的方式,把容積調整為20毫升。如此所製得的溶 液,其濃度為5mg/ml。 審 Μ 3 依據實例2的步驟製備一種溶液*其中含有0.1Μ的甘膽酸 鈉及D . 1 Μ的磷脂醯膽鹼,之後加人過剩的阿加托班,持縝 攪拌4 S小時,並Κ 一個〇 . 2 2 w m的薄膜。如此所製得的溶 液,其濃度為1 1 · 3 m g / ΠΙ1。 棄例 4 . 依據賁例3的步驟,以一種含有Q.075M的甘膽酸鈉的溶液 為起始,如此所製得的溶液•其濃度為9»»g/ml。 實 例 5._ 依據賁例3的步驟,以一種含有0.15M的甘膽酸納及〇.15M 的磷脂豳膽鹼的溶液為起始,如此所製得的溶液,其湄度 為 1 6 . 9 ID g / IH1。 (請先閲讀背面之注意事項再填寫本頁) a 例 6 有 含 種 1 Μ 驟 步 的 3 例 霣 據 依 及 鹼 膽 醯 脂 磷 經濟部中央標率局負工消费合作社印製 度 湄 其 液 溶 的 得 所 此 如 始 起 為 液 溶 的 納 酸10 膽/m 磺nsg 牛13 的為 7 例 審 及 -納始 酸起 膽為 磺液 牛溶 % j 5 合 6 曰tbl*= ·ί»1 Ms的/Bl 15鹼mg o膽6 有醯20 含脂為 種瞵度 一 的濃 ΚΜ其 5 f 1 > 驟0.液 步及溶 的鈉的 3 酸得 例膽製 實甘所 據 % 此 依35如 本紙張尺度適用中國國家橾隼(CNS ) A4規格(210X297公釐) 卜 43 62 9 5 at __B7_ 五、發明説明(9 ) 依據實例3的步驟,以一種含有0.15 Μ牛磺膽酸鈉及0.15M 的磷脂醢膽鹼及磷脂醯乙醇胺的温合溶液為起始,如此所 製得的溶液•其濃度為2Q.lmg/nl。 依據本發明所製成之阿加托班溶液得K下列方式投與 ,包括:非口服(注射方式)、口服、鼻用、哏用、或反 眼用(retro-ocular)的途徑。 ---L----丨裝------訂-----^旅 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局負工消資合作杜印製 本紙張尺度適用中國國家標隼(CNS ) Μ規格(210X297公釐)
Claims (1)
- 經濟部中央樣準局貝工消费合作杜印袈 AS 436295 〆 & < U B8 C8 D8 六'申請專利範圍 止 1' r· ., η a » c 1 * 一 種 濃 嫌 之 阿 加托 班(argat r 〇 b a η)水 溶 液 ,其 特 徵在於:含 有 阿 加 托 班 種或 多 種 撖 胞 形 成 劑 > 及一 種 或多種類胞 化 合 物 f 其 中類 胞類 化 合 物 對 微 胞 形 成 成份 的 克分子比是 介 於 0 ‘ 1/ 1 至2/ 1之 間 9 微 胞 形 成 m 的 濃度 係 介於 0.01 至 0 .5Μ 之 間, 及阿 加 托 班 灌 度 介 於 1B g/ B 1 至 2 lug/ nl之 間 0 2 ·如 請 專 利 範 圍第 1項 所 述 之 溶 液 其 特 徽在 於 該微胞形成劑係選自通式(I)的15酸衍生物: .(請先聞讀背面之注意事項再填窝本頁)其中,Rl、R2及R3各代表氫原子、羥基、或氣代環外 基團iketo exocyclic group) ,R4則代表羧基、或是一 種其醢胺鐽(a^ide)鍵接至氨基酸之氨基的羧基·, 其甾族(steroid)结構中,可含有一個或兩個雙鍵。 3 *如申請專利範園第2項所逑之溶液*其特徵在於 該膽酸衍生物係圼鐮金羼鹽的形式。 4·如申請專利範画第1至3項之任一項所述之溶液 -1 - 本紙張尺度逋用中國國家橾準(CNS )八4規淋(210X297公釐) ,tT 436295 8 8 8 0D ABCD 六、申請專利範圍 ,其特擞在於該膽類脂化合物係一種磷胞。 5 ·如申謅專利範圍第4項所述之溶液,其特激在於 該磷脂是一種磷脂醢鼸_。 6 *如申請專利範圍第1至3項之任一項所述之溶液 ,其特徵在於溶液中含有一些製備液態葯麵形式或固戆葯 劑形式所常用的賦形劑,其在重組後能重新諝回液態形式 0 (請先閏讀背面之注意事項再填寫本頁) 訂 經濟部中央橾準局貝工消费合作社印裝 -2 - 本紙铢尺度適用中國國家梯準(CNS ) A4规格(2IOX297公釐) 經濟部中央樣準局貝工消费合作杜印袈 AS 436295 〆 & < U B8 C8 D8 六'申請專利範圍 止 1' r· ., η a » c 1 * 一 種 濃 嫌 之 阿 加托 班(argat r 〇 b a η)水 溶 液 ,其 特 徵在於:含 有 阿 加 托 班 種或 多 種 撖 胞 形 成 劑 > 及一 種 或多種類胞 化 合 物 f 其 中類 胞類 化 合 物 對 微 胞 形 成 成份 的 克分子比是 介 於 0 ‘ 1/ 1 至2/ 1之 間 9 微 胞 形 成 m 的 濃度 係 介於 0.01 至 0 .5Μ 之 間, 及阿 加 托 班 灌 度 介 於 1B g/ B 1 至 2 lug/ nl之 間 0 2 ·如 請 專 利 範 圍第 1項 所 述 之 溶 液 其 特 徽在 於 該微胞形成劑係選自通式(I)的15酸衍生物: .(請先聞讀背面之注意事項再填窝本頁)其中,Rl、R2及R3各代表氫原子、羥基、或氣代環外 基團iketo exocyclic group) ,R4則代表羧基、或是一 種其醢胺鐽(a^ide)鍵接至氨基酸之氨基的羧基·, 其甾族(steroid)结構中,可含有一個或兩個雙鍵。 3 *如申請專利範園第2項所逑之溶液*其特徵在於 該膽酸衍生物係圼鐮金羼鹽的形式。 4·如申請專利範画第1至3項之任一項所述之溶液 -1 - 本紙張尺度逋用中國國家橾準(CNS )八4規淋(210X297公釐) ,tT
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9401195A FR2715566B1 (fr) | 1994-02-03 | 1994-02-03 | Solutions aqueuses concentrées d'argatroban. |
Publications (1)
Publication Number | Publication Date |
---|---|
TW436295B true TW436295B (en) | 2001-05-28 |
Family
ID=9459714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW084100521A TW436295B (en) | 1994-02-03 | 1995-01-21 | Concentrated aqueous solutions of argatroban |
Country Status (25)
Country | Link |
---|---|
US (1) | US5679690A (zh) |
EP (1) | EP0669131B1 (zh) |
JP (1) | JP3027103B2 (zh) |
KR (1) | KR100257692B1 (zh) |
CN (1) | CN1054743C (zh) |
AT (1) | ATE179327T1 (zh) |
AU (1) | AU687133B2 (zh) |
CA (1) | CA2141704C (zh) |
CZ (1) | CZ284611B6 (zh) |
DE (1) | DE69509279T2 (zh) |
DK (1) | DK0669131T3 (zh) |
ES (1) | ES2132547T3 (zh) |
FI (1) | FI950459A (zh) |
FR (1) | FR2715566B1 (zh) |
GR (1) | GR3030149T3 (zh) |
HK (1) | HK1013623A1 (zh) |
HU (1) | HU218220B (zh) |
IL (1) | IL112527A (zh) |
NO (1) | NO307324B1 (zh) |
NZ (1) | NZ270445A (zh) |
PL (1) | PL178586B1 (zh) |
RU (1) | RU2136282C1 (zh) |
SK (1) | SK12795A3 (zh) |
TW (1) | TW436295B (zh) |
ZA (1) | ZA95837B (zh) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840733A (en) * | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
US5786153A (en) * | 1996-09-12 | 1998-07-28 | Chiron Diagnostics Corporation | Prevention of probe coating on automated analyzers using a non-denaturing surfactant |
EP1004309A4 (en) * | 1997-05-27 | 2001-01-17 | Senju Pharma Co | AQUEOUS PREPARATIONS CONTAINING ISRAPAFANT |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
FR2793412B1 (fr) * | 1999-05-11 | 2001-07-27 | Synthelabo | Formulations galeniques d'argatroban pour administration sous-cutanee |
KR100399373B1 (ko) * | 2000-12-20 | 2003-09-26 | 주식회사 아이센스 | 콜란산 고리를 포함하는 디글라이콜릭 디아마이드 유도체,그의 제조방법 및 용도 |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
CN100344624C (zh) * | 2003-03-20 | 2007-10-24 | 三菱制药株式会社 | 含有精氨酰胺类的医药制剂 |
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
CA2556331A1 (en) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
JP5189980B2 (ja) * | 2005-09-01 | 2013-04-24 | バクスター・インターナショナル・インコーポレイテッド | 可溶化剤として酸を含むアルガトロバン処方物 |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US20080064937A1 (en) | 2006-06-07 | 2008-03-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
WO2008027958A2 (en) * | 2006-08-31 | 2008-03-06 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US7687516B2 (en) * | 2006-09-27 | 2010-03-30 | Eagle Pharmaceuticals, Inc. | Alcohol free formulation of argatroban |
CA2669727C (en) * | 2006-09-27 | 2014-10-28 | Eagle Pharmaceuticals, Inc. | Alcohol free formulation of argatroban |
US20100076019A1 (en) * | 2006-10-11 | 2010-03-25 | Eagle Pharmaceuticals, Inc. | Alcohol free formulation of argatroban |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US8703204B2 (en) | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
WO2008135828A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
EP2162120B1 (en) | 2007-06-04 | 2016-05-04 | Bend Research, Inc | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
US9545384B2 (en) | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
EP2231169B1 (en) | 2007-12-06 | 2016-05-04 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
US7915290B2 (en) * | 2008-02-29 | 2011-03-29 | Baxter International Inc. | Argatroban formulations and methods for making and using same |
US20090221637A1 (en) * | 2008-02-29 | 2009-09-03 | Baxter International Inc. | Solid-state salt argatroban formulations and methods for producing and using the same |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
US9184490B2 (en) | 2009-05-29 | 2015-11-10 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
EP2473099A4 (en) | 2009-08-31 | 2015-01-14 | Abbott Diabetes Care Inc | ANALYTICAL SUBSTANCE MONITORING SYSTEM AND METHODS OF MANAGING ENERGY AND NOISE |
US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
CN102366410B (zh) * | 2011-09-14 | 2013-05-29 | 海南灵康制药有限公司 | 一种阿加曲班脂质体注射剂 |
US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
WO2015006679A2 (en) | 2013-07-11 | 2015-01-15 | Aqua Turf International, Inc. | Air filtration mask with opening front cover |
DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
US20220218608A1 (en) * | 2019-05-10 | 2022-07-14 | Fordoz Pharma Corp. | Injectable polymer nanoparticle compositions of antithrombotic agents and methods thereof |
CN110478471B (zh) * | 2019-09-17 | 2020-04-10 | 鲁南制药集团股份有限公司 | 一种阿加曲班注射液及其制备方法 |
JP7027576B1 (ja) | 2020-07-03 | 2022-03-01 | 東芝三菱電機産業システム株式会社 | 無停電電源システム |
EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
CN113855635A (zh) * | 2021-10-20 | 2021-12-31 | 陇南市第一人民医院 | 一种阿加曲班注射液脂质体及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE48623B1 (en) * | 1978-08-31 | 1985-03-20 | Mitsubishi Chem Ind | Alpha-(n-arylsulfonyl-l-argininamides,processes for their preparation and pharmaceutical compositions containing these substances |
JPS6431727A (en) * | 1987-07-28 | 1989-02-02 | Mitsubishi Chem Ind | Dissolution of argininamide and drug composition containing argininamides |
JPH02129123A (ja) * | 1988-11-07 | 1990-05-17 | Mitsubishi Kasei Corp | 抗血液凝固剤 |
CA2091715A1 (en) * | 1992-03-18 | 1993-09-19 | Mitsubishi Kasei Corporation | Argatroban preparations for ophthalmic use |
EP0566897A3 (en) * | 1992-04-07 | 1994-07-06 | Hoechst Ag | The complete gene (cefg) encoding the acetyl-coa: deacetylcephalosporin c acetyltransferase of cephalosporium acremonium, its isolation and use |
-
1994
- 1994-02-03 FR FR9401195A patent/FR2715566B1/fr not_active Expired - Fee Related
-
1995
- 1995-01-21 TW TW084100521A patent/TW436295B/zh active
- 1995-01-28 CN CN95101782A patent/CN1054743C/zh not_active Expired - Fee Related
- 1995-02-02 US US08/382,791 patent/US5679690A/en not_active Expired - Lifetime
- 1995-02-02 KR KR1019950001836A patent/KR100257692B1/ko not_active IP Right Cessation
- 1995-02-02 DK DK95400214T patent/DK0669131T3/da active
- 1995-02-02 NZ NZ270445A patent/NZ270445A/en unknown
- 1995-02-02 AU AU11543/95A patent/AU687133B2/en not_active Ceased
- 1995-02-02 EP EP95400214A patent/EP0669131B1/fr not_active Expired - Lifetime
- 1995-02-02 ES ES95400214T patent/ES2132547T3/es not_active Expired - Lifetime
- 1995-02-02 CA CA002141704A patent/CA2141704C/fr not_active Expired - Lifetime
- 1995-02-02 AT AT95400214T patent/ATE179327T1/de not_active IP Right Cessation
- 1995-02-02 RU RU95101387A patent/RU2136282C1/ru active
- 1995-02-02 SK SK127-95A patent/SK12795A3/sk unknown
- 1995-02-02 CZ CZ95271A patent/CZ284611B6/cs not_active IP Right Cessation
- 1995-02-02 HU HU9500308A patent/HU218220B/hu not_active IP Right Cessation
- 1995-02-02 FI FI950459A patent/FI950459A/fi unknown
- 1995-02-02 ZA ZA95837A patent/ZA95837B/xx unknown
- 1995-02-02 JP JP7015900A patent/JP3027103B2/ja not_active Expired - Lifetime
- 1995-02-02 IL IL11252795A patent/IL112527A/xx not_active IP Right Cessation
- 1995-02-02 DE DE69509279T patent/DE69509279T2/de not_active Expired - Fee Related
- 1995-02-02 NO NO950377A patent/NO307324B1/no unknown
- 1995-02-02 PL PL95307041A patent/PL178586B1/pl unknown
-
1998
- 1998-12-23 HK HK98114973A patent/HK1013623A1/xx not_active IP Right Cessation
-
1999
- 1999-05-06 GR GR990401237T patent/GR3030149T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW436295B (en) | Concentrated aqueous solutions of argatroban | |
DK175662B1 (da) | Blandingsmicelleoplösninger med ikke-steroide inflammationshæmmmere | |
CA1136988A (en) | Aqueous composition | |
US5350769A (en) | Antiinflammatory gel preparation | |
JP2511417B2 (ja) | リポソ−ム形成用組成物および形成方法 | |
JP5856144B2 (ja) | 経皮吸収用高分子‐リポソームナノ複合体組成物及びその製造方法 | |
CA2279279C (en) | Lipid complexes and liposomes of highly insoluble platinum complexes | |
IE46037B1 (en) | Injection solutions containing micelle-forming agents | |
US5230899A (en) | Methods and compositions for making liposomes | |
US4328222A (en) | Pharmaceutical compositions for parenteral or local administration | |
BRPI0510778B1 (pt) | Composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição | |
JP2009521400A (ja) | ヒアルロン酸リン脂質合成物を含む経口関節機能改善と保護剤 | |
US8912162B2 (en) | Parenteral formulations of elacytarabine derivatives | |
EP0600395B1 (en) | Antinflammatory and analgesic diclofenac gel preparation | |
US8871252B2 (en) | pH-responsive liposome | |
EP1035837B1 (en) | Lipid compositions and their use | |
JPS63192716A (ja) | 非経口投与用懸濁液 | |
JPH035426A (ja) | 安定な電解質含有レシチン分散液 | |
JPS6236331A (ja) | 抗感染症剤ならびに免疫賦活剤 | |
FI94835C (fi) | Menetelmä 2-fenyyli-1,2-bentsisoselenatsol-3(2H)-onin stabiilien parenteraalisten liuosten valmistamiseksi | |
WO2020004193A1 (ja) | 外用組成物 | |
PT90134B (pt) | Processo para a preparacao de composicoes farmaceuticas com propriedades de preservacao e restauracao da saude da pele | |
WO2007006232A1 (fr) | Complexe de phospholipide et d’acide hyaluronique et procédé de préparation | |
JPH01175944A (ja) | 虚血性疾患予防及び治療剤 | |
JPH0528205B2 (zh) |